Review





Similar Products

98
MedChemExpress protein a g magnetic beads
Protein A G Magnetic Beads, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protein a g magnetic beads/product/MedChemExpress
Average 98 stars, based on 1 article reviews
protein a g magnetic beads - by Bioz Stars, 2026-02
98/100 stars
  Buy from Supplier

99
Thermo Fisher streptavidin magnetic beads
Streptavidin Magnetic Beads, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/streptavidin magnetic beads/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
streptavidin magnetic beads - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier

90
BioSpec zirconia beads diameter
Zirconia Beads Diameter, supplied by BioSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/zirconia beads diameter/product/BioSpec
Average 90 stars, based on 1 article reviews
zirconia beads diameter - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Qiagen bead-beating homogenizer tissuelyser lt
Bead Beating Homogenizer Tissuelyser Lt, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bead-beating homogenizer tissuelyser lt/product/Qiagen
Average 90 stars, based on 1 article reviews
bead-beating homogenizer tissuelyser lt - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

97
Vazyme Biotech Co vahts rna clean beads
Vahts Rna Clean Beads, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vahts rna clean beads/product/Vazyme Biotech Co
Average 97 stars, based on 1 article reviews
vahts rna clean beads - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier

97
Vazyme Biotech Co n412 02
N412 02, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/n412 02/product/Vazyme Biotech Co
Average 97 stars, based on 1 article reviews
n412 02 - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier

98
Miltenyi Biotec cd19 beads
NKG2A-edited CAR NK cells eliminate <t>CD19-negative</t> target cells resistant to conventional CAR NK cells (A) Specific lysis of 721.45 CD19 KO cells by engineered NK cells (left) or CAR NK cells (right). Cells were co-cultured for 4–5 h at an effector to target ratio of 5:1. (B) Schematic of repetitive stimulation assay. 0.1 × 10 6 NK or CAR NK cells were seeded at day 0, and 0.1 × 10 6 <t>CD19-positive</t> 721.45 cells (target cells) were added every 2–3 days for 14 days. IL-2 was added 2×/week until day 12. Target cells added on day 7 were labeled with PKH26 and on day 14 with PKH67. Data shown in (C–H) were generated using this setup. (C) Expression of CD19 (histograms) and relative MFI of CD19 on total target cells (live CD56 − ) and representative flow cytometry plots on day 14 after co-culture with NK (top) or CAR NK (bottom) cells. Relative MFI is calculated by dividing by MFI of CD19 on target cells cultured alone. (D) Representative expression of PKH26 (target cells added day 7) and PKH67 (target cells added day 14) on total target cells (live CD56 − ) after co-culture with NK or CAR NK cells for 14 days. (E and F) Frequency of remaining live PKH26 + target cells (added on day 7) on day 14 after co-culture with NK cells (E) or CAR NK cells (F). Target cells alone (721.45 only) were not included in the statistical analysis. (G and H) Frequency of remaining live PKH67 + target cells (added on day 14 and co-cultured for 4–5 h before readout) after co-culture with NK cells (G) or CAR NK cells (H). Target cells alone (721.45 only) were not included in the statistical analysis. (A–H) n = 6–9 (individual donors). One-way ANOVA. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
Cd19 Beads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd19 beads/product/Miltenyi Biotec
Average 98 stars, based on 1 article reviews
cd19 beads - by Bioz Stars, 2026-02
98/100 stars
  Buy from Supplier

99
Thermo Fisher dynabeads myone streptavidin c1 beads
NKG2A-edited CAR NK cells eliminate <t>CD19-negative</t> target cells resistant to conventional CAR NK cells (A) Specific lysis of 721.45 CD19 KO cells by engineered NK cells (left) or CAR NK cells (right). Cells were co-cultured for 4–5 h at an effector to target ratio of 5:1. (B) Schematic of repetitive stimulation assay. 0.1 × 10 6 NK or CAR NK cells were seeded at day 0, and 0.1 × 10 6 <t>CD19-positive</t> 721.45 cells (target cells) were added every 2–3 days for 14 days. IL-2 was added 2×/week until day 12. Target cells added on day 7 were labeled with PKH26 and on day 14 with PKH67. Data shown in (C–H) were generated using this setup. (C) Expression of CD19 (histograms) and relative MFI of CD19 on total target cells (live CD56 − ) and representative flow cytometry plots on day 14 after co-culture with NK (top) or CAR NK (bottom) cells. Relative MFI is calculated by dividing by MFI of CD19 on target cells cultured alone. (D) Representative expression of PKH26 (target cells added day 7) and PKH67 (target cells added day 14) on total target cells (live CD56 − ) after co-culture with NK or CAR NK cells for 14 days. (E and F) Frequency of remaining live PKH26 + target cells (added on day 7) on day 14 after co-culture with NK cells (E) or CAR NK cells (F). Target cells alone (721.45 only) were not included in the statistical analysis. (G and H) Frequency of remaining live PKH67 + target cells (added on day 14 and co-cultured for 4–5 h before readout) after co-culture with NK cells (G) or CAR NK cells (H). Target cells alone (721.45 only) were not included in the statistical analysis. (A–H) n = 6–9 (individual donors). One-way ANOVA. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
Dynabeads Myone Streptavidin C1 Beads, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dynabeads myone streptavidin c1 beads/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
dynabeads myone streptavidin c1 beads - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier

96
IBA Lifesciences strep tactin sepharose beads
NKG2A-edited CAR NK cells eliminate <t>CD19-negative</t> target cells resistant to conventional CAR NK cells (A) Specific lysis of 721.45 CD19 KO cells by engineered NK cells (left) or CAR NK cells (right). Cells were co-cultured for 4–5 h at an effector to target ratio of 5:1. (B) Schematic of repetitive stimulation assay. 0.1 × 10 6 NK or CAR NK cells were seeded at day 0, and 0.1 × 10 6 <t>CD19-positive</t> 721.45 cells (target cells) were added every 2–3 days for 14 days. IL-2 was added 2×/week until day 12. Target cells added on day 7 were labeled with PKH26 and on day 14 with PKH67. Data shown in (C–H) were generated using this setup. (C) Expression of CD19 (histograms) and relative MFI of CD19 on total target cells (live CD56 − ) and representative flow cytometry plots on day 14 after co-culture with NK (top) or CAR NK (bottom) cells. Relative MFI is calculated by dividing by MFI of CD19 on target cells cultured alone. (D) Representative expression of PKH26 (target cells added day 7) and PKH67 (target cells added day 14) on total target cells (live CD56 − ) after co-culture with NK or CAR NK cells for 14 days. (E and F) Frequency of remaining live PKH26 + target cells (added on day 7) on day 14 after co-culture with NK cells (E) or CAR NK cells (F). Target cells alone (721.45 only) were not included in the statistical analysis. (G and H) Frequency of remaining live PKH67 + target cells (added on day 14 and co-cultured for 4–5 h before readout) after co-culture with NK cells (G) or CAR NK cells (H). Target cells alone (721.45 only) were not included in the statistical analysis. (A–H) n = 6–9 (individual donors). One-way ANOVA. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
Strep Tactin Sepharose Beads, supplied by IBA Lifesciences, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/strep tactin sepharose beads/product/IBA Lifesciences
Average 96 stars, based on 1 article reviews
strep tactin sepharose beads - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

Image Search Results


NKG2A-edited CAR NK cells eliminate CD19-negative target cells resistant to conventional CAR NK cells (A) Specific lysis of 721.45 CD19 KO cells by engineered NK cells (left) or CAR NK cells (right). Cells were co-cultured for 4–5 h at an effector to target ratio of 5:1. (B) Schematic of repetitive stimulation assay. 0.1 × 10 6 NK or CAR NK cells were seeded at day 0, and 0.1 × 10 6 CD19-positive 721.45 cells (target cells) were added every 2–3 days for 14 days. IL-2 was added 2×/week until day 12. Target cells added on day 7 were labeled with PKH26 and on day 14 with PKH67. Data shown in (C–H) were generated using this setup. (C) Expression of CD19 (histograms) and relative MFI of CD19 on total target cells (live CD56 − ) and representative flow cytometry plots on day 14 after co-culture with NK (top) or CAR NK (bottom) cells. Relative MFI is calculated by dividing by MFI of CD19 on target cells cultured alone. (D) Representative expression of PKH26 (target cells added day 7) and PKH67 (target cells added day 14) on total target cells (live CD56 − ) after co-culture with NK or CAR NK cells for 14 days. (E and F) Frequency of remaining live PKH26 + target cells (added on day 7) on day 14 after co-culture with NK cells (E) or CAR NK cells (F). Target cells alone (721.45 only) were not included in the statistical analysis. (G and H) Frequency of remaining live PKH67 + target cells (added on day 14 and co-cultured for 4–5 h before readout) after co-culture with NK cells (G) or CAR NK cells (H). Target cells alone (721.45 only) were not included in the statistical analysis. (A–H) n = 6–9 (individual donors). One-way ANOVA. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Journal: Molecular Therapy Oncology

Article Title: Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells

doi: 10.1016/j.omton.2026.201126

Figure Lengend Snippet: NKG2A-edited CAR NK cells eliminate CD19-negative target cells resistant to conventional CAR NK cells (A) Specific lysis of 721.45 CD19 KO cells by engineered NK cells (left) or CAR NK cells (right). Cells were co-cultured for 4–5 h at an effector to target ratio of 5:1. (B) Schematic of repetitive stimulation assay. 0.1 × 10 6 NK or CAR NK cells were seeded at day 0, and 0.1 × 10 6 CD19-positive 721.45 cells (target cells) were added every 2–3 days for 14 days. IL-2 was added 2×/week until day 12. Target cells added on day 7 were labeled with PKH26 and on day 14 with PKH67. Data shown in (C–H) were generated using this setup. (C) Expression of CD19 (histograms) and relative MFI of CD19 on total target cells (live CD56 − ) and representative flow cytometry plots on day 14 after co-culture with NK (top) or CAR NK (bottom) cells. Relative MFI is calculated by dividing by MFI of CD19 on target cells cultured alone. (D) Representative expression of PKH26 (target cells added day 7) and PKH67 (target cells added day 14) on total target cells (live CD56 − ) after co-culture with NK or CAR NK cells for 14 days. (E and F) Frequency of remaining live PKH26 + target cells (added on day 7) on day 14 after co-culture with NK cells (E) or CAR NK cells (F). Target cells alone (721.45 only) were not included in the statistical analysis. (G and H) Frequency of remaining live PKH67 + target cells (added on day 14 and co-cultured for 4–5 h before readout) after co-culture with NK cells (G) or CAR NK cells (H). Target cells alone (721.45 only) were not included in the statistical analysis. (A–H) n = 6–9 (individual donors). One-way ANOVA. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: EBV-transformed LCLs from allogeneic human fetal liver tissue were generated by isolating CD19 + cells by magnetic-activated cell sorting with CD19 beads (Miltenyi, Cat. 130-050-301) and then infected with EBV B95-8, produced as previously described at a multiplicity of infection (MOI) of 0.05–0.15.

Techniques: Lysis, Cell Culture, Labeling, Generated, Expressing, Flow Cytometry, Co-Culture Assay

Increased cytotoxicity of NKG2A-edited CAR NK cells against CD19-negative BCP-ALL PDX (A) CD19 and (B) HLA-E expression of BCP-ALL PDX by flow cytometry. (C) Specific lysis of PDX1 and PDX2 after co-culture with control NK cells (NK mock) or CAR NK cells (CAR mock). Co-culture at E:T ratio 5:1 for 4 h. (D) Specific lysis of PDX1 after 4 h co-culture at 1:1 E:T ratio. (E) Data from (D) shown as relative increase in killing of engineered CAR NK cells compared with controls (CAR mock). (F–H) Specific lysis of PDX2 after 20 h co-culture at 5:1 E:T ratio with NK (F) or CAR NK (G) cells. (H) Data from (G) shown as relative increase in killing of engineered CAR NK cells compared with controls (CAR mock). (C) n = 3 (individual donors), paired t test. (D–G) n = 3 (individual donors), repeated measures one-way ANOVA. Engineered NK cells shown in this figure were generated from bulk NK cells (not NKG2A + NK cells) as the starting population. ∗ p < 0.05.

Journal: Molecular Therapy Oncology

Article Title: Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells

doi: 10.1016/j.omton.2026.201126

Figure Lengend Snippet: Increased cytotoxicity of NKG2A-edited CAR NK cells against CD19-negative BCP-ALL PDX (A) CD19 and (B) HLA-E expression of BCP-ALL PDX by flow cytometry. (C) Specific lysis of PDX1 and PDX2 after co-culture with control NK cells (NK mock) or CAR NK cells (CAR mock). Co-culture at E:T ratio 5:1 for 4 h. (D) Specific lysis of PDX1 after 4 h co-culture at 1:1 E:T ratio. (E) Data from (D) shown as relative increase in killing of engineered CAR NK cells compared with controls (CAR mock). (F–H) Specific lysis of PDX2 after 20 h co-culture at 5:1 E:T ratio with NK (F) or CAR NK (G) cells. (H) Data from (G) shown as relative increase in killing of engineered CAR NK cells compared with controls (CAR mock). (C) n = 3 (individual donors), paired t test. (D–G) n = 3 (individual donors), repeated measures one-way ANOVA. Engineered NK cells shown in this figure were generated from bulk NK cells (not NKG2A + NK cells) as the starting population. ∗ p < 0.05.

Article Snippet: EBV-transformed LCLs from allogeneic human fetal liver tissue were generated by isolating CD19 + cells by magnetic-activated cell sorting with CD19 beads (Miltenyi, Cat. 130-050-301) and then infected with EBV B95-8, produced as previously described at a multiplicity of infection (MOI) of 0.05–0.15.

Techniques: Expressing, Flow Cytometry, Lysis, Co-Culture Assay, Control, Generated